Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305819 | 0.85 | CA12 (0.36) | KDM4EMAPK1HPGDL3MBTL1CA12 | |
| SCHEMBL20187643 | 0.82 | TSHR (0.36) | KDM4EMAPK1HPGDCA12CA1 | |
| SCHEMBL31267942 | 0.82 | TSHR (0.36) | KDM4EMAPK1HPGDCA12CA1 | |
| SCHEMBL31368738 | 0.81 | MAPK1 (0.46) | CYP3A4ACHEKDM4EMAPK1ALDH1A1 | |
| SCHEMBL31368751 | 0.81 | MAPT (0.41) | KDM4EMAPK1ALDH1A1LMNAMRGPRX4 | |
| SCHEMBL19146730 | 0.80 | CYP3A4 (0.38) | CYP3A4ACHEKDM4EMAPK1HPGD | |
| SCHEMBL24558286 | 0.79 | TSHR (0.38) | KDM4EMAPK1HPGDL3MBTL1CA12 | |
| SCHEMBL31368709 | 0.79 | POLB (0.47) | KDM4EMAPK1HPGDL3MBTL1TSHR | |
| SCHEMBL31107236 | 0.79 | TSHR (0.38) | KDM4EMAPK1HPGDL3MBTL1CA12 | |
| Hydrochloric Acid SCHEMBL19127550 | 0.79 | CYP3A4 (0.37) | CYP3A4ACHEKDM4EMAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3768260-B1 | OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024251211-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024251212-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019182925-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182925-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | CYP3A4 865/4885ACHE 851/4885KDM4E 4048/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | CYP3A4 843/4885ACHE 1020/4885KDM4E 3914/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | CYP3A4 638/4885ACHE 1231/4885KDM4E 4296/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | CYP3A4 865/4885ACHE 851/4885KDM4E 4048/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | CYP3A4 865/4885ACHE 851/4885KDM4E 4048/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | CYP3A4 865/4885ACHE 851/4885KDM4E 4048/4885 |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | CYP3A4 865/4885ACHE 851/4885KDM4E 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.